文献速递湿疹皮炎与荨麻疹

度普利尤单抗不影响疫苗诱导免疫的相关指标:一项在中重度特应性皮炎成人中开展的随机安慰剂对照试验

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2018-08-06

本随机双盲安慰剂对照研究纳入中重度特应性皮炎成人,每周皮下注射度普利尤单抗300 mg或安慰剂共16周,第12周接种单剂Tdap和四价脑膜炎球菌多糖疫苗;两组对破伤风和脑膜炎球菌多糖疫苗的阳性免疫应答比例相似,度普利尤单抗显著降低总血清IgE并改善特应性皮炎疗效终点(P < .001)。

要点

  • 度普利尤单抗组与安慰剂组对破伤风疫苗的阳性免疫应答比例分别为83.3%和83.7%,对脑膜炎球菌多糖疫苗分别为86.7%和87.0%。
  • 第32周时,度普利尤单抗组Tdap-IgE血清阴性比例为62.2%,安慰剂组为34.8%。
  • 度普利尤单抗改善特应性皮炎关键疗效终点(P < .001);注射部位反应和结膜炎在度普利尤单抗组更常见,安慰剂组特应性皮炎加重更频繁。

核心结论

  • 度普利尤单抗不影响对破伤风和脑膜炎球菌多糖疫苗的免疫应答,显著降低IgE,并较安慰剂改善特应性皮炎严重度指标,安全性可接受。

研究设计与样本

  • 随机双盲安慰剂对照研究(NCT02210780),中重度特应性皮炎成人每周接受度普利尤单抗300 mg或安慰剂共16周,第12周接种单剂Tdap和四价脑膜炎球菌多糖疫苗。
  • 共178例患者完成研究。

主要发现

  • 度普利尤单抗组与安慰剂组对破伤风疫苗的阳性免疫应答(抗体滴度≥4倍升高或抗体滴度≥8)比例分别为83.3%和83.7%。
  • 度普利尤单抗组与安慰剂组对脑膜炎球菌多糖疫苗的阳性免疫应答比例分别为86.7%和87.0%。
  • 度普利尤单抗显著降低总血清IgE;第32周时度普利尤单抗组Tdap-IgE血清阴性比例为62.2%,安慰剂组为34.8%。
  • 度普利尤单抗改善特应性皮炎关键疗效终点(P < .001)。
  • 注射部位反应和结膜炎在度普利尤单抗组更常见,特应性皮炎加重在安慰剂组更频繁。

局限性

  • 入组前患者的既往疫苗接种状态未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of dupilumab, an anti-interleukin (IL) 4 receptor α antibody that inhibits IL-4 and IL-13 signaling, on vaccine responses of patients with atopic dermatitis (AD) is unknown. OBJECTIVES: To assess T-cell-dependent and T-cell-independent humoral immune responses to tetanus and meningococcal vaccines, IgE seroconversion to tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination, and dupilumab efficacy and safety. METHODS: In a randomized, double-blinded, placebo-controlled study (NCT02210780), adults with moderate-to-severe AD received dupilumab (300 mg) or placebo weekly for 16 weeks, and single doses of Tdap and quadrivalent meningococcal polysaccharide vaccines at week 12. Primary endpoint was proportion of patients achieving satisfactory IgG response to tetanus toxoid at week 16. RESULTS: In total, 178 patients completed the study. Similar positive immune responses (≥4-fold increase in antibody titer, or an antibody titer of ≥8) were achieved in the dupilumab and placebo groups to tetanus (83.3% and 83.7%, respectively) and meningococcal polysaccharide (86.7% and 87.0%, respectively). Dupilumab significantly decreased total serum IgE; most dupilumab-treated patients were Tdap-IgE seronegative at week 32 (62.2% dupilumab and 34.8% placebo). Dupilumab improved key AD efficacy endpoints (P < .001). Injection-site reactions and conjunctivitis were more common with dupilumab; AD exacerbations more frequent with placebo. LIMITATION: Patients' prior vaccination status was not available before enrollment. CONCLUSION: Dupilumab did not affect responses to the vaccines studied, significantly decreased IgE, and improved measures of AD severity versus placebo, with an acceptable safety profile.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2018. PMID: 30092324. doi:10.1016/j.jaad.2018.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。